Description: Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovering, developing, and commercializing novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. Disc Medicine, Inc. is based in Watertown, Massachusetts.
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-08-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |